Effect of formulation pH on transport of naltrexone species and pore closure in microneedle-enhanced transdermal drug delivery

Molecular Pharmaceutics

Volumn 10, Issue 6, 2013, Pages 2331-2339

  Ghosh, Priyanka ^a,b   Brogden, Nicole K ^a   Stinchcomb, Audra L ^a,b,c  

^a University of Kentucky   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c AllTranz Inc   (United States)

Author keywords

impedance spectroscopy; microneedle; micropore closure; permeability; transdermal

Indexed keywords

NALTREXONE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; MICRONEEDLE; NONHUMAN; PH; PRIORITY JOURNAL; SKIN IRRITATION; SKIN SENSITIZATION; TRANSDERMAL DRUG ADMINISTRATION; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; ANIMALS; DIELECTRIC SPECTROSCOPY; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; NALTREXONE; SKIN ABSORPTION; SOLUBILITY; SWINE; VISCOSITY; WOUND HEALING;

EID: 84878629186     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3007083     Document Type: Article

References (46)

1. Flynn, G. Cutaneous and Transdermal Delivery-Processes and Systems of Delivery. In Anonymous Modern Pharmaceutics, 4 th ed.; Informa Healthcare: 2002
2. Prausnitz, M. R.; Langer, R. Transdermal drug delivery Nat. Biotechnol. 2008, 26, 1261-1268
3. Elias, P. M.; Cooper, E. R.; Korc, A.; Brown, B. E. Percutaneous Transport in Relation to Stratum Corneum Structure and Lipid Composition J. Invest. Dermatol. 1981, 76, 297-301
4. Barry, B. W. Novel mechanisms and devices to enable successful transdermal drug delivery Eur. J. Pharm. Sci. 2001, 14, 101-114
5. Bos, J. D.; Meinardi, M. M. H. M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs Exp. Dermatol. 2000, 9, 165-169
6. Prausnitz, M. R.; Mitragotri, S.; Langer, R. Current status and future potential of transdermal drug delivery Nat. Rev. Drug Discovery 2004, 3, 115-124
7. Chen, L.; Han, L.; Lian, G. Recent advances in predicting skin permeability of hydrophilic solutes Adv. Drug Delivery Rev. 2013, 65 (2) 295-305
8. Prausnitz, M. R. Microneedles for transdermal drug delivery Adv. Drug Delivery Rev. 2004, 56, 581-587
9. Gomaa, Y. A.; Morrow, D. I. J.; Garland, M. J.; Donnelly, R. F.; El-Khordagui, L. K.; Meidan, V. M. Effects of microneedle length, density, insertion time and multiple applications on human skin barrier function: Assessments by transepidermal water loss Toxicol. In Vitro 2010, 24, 1971-1978
10. Gill, H. S.; Denson, D. D.; Burris, B. A.; Prausnitz, M. R. Effect of Microneedle Design on Pain in Human Volunteers Clin. J. Pain 2008, 24, 585-594 10.1097/AJP.0b013e31816778f9
11. Banks, S.; Pinninti, R.; Gill, H.; Crooks, P.; Prausnitz, M.; Stinchcomb, A. Flux Across Microneedle-treated Skin is Increased by Increasing Charge of Naltrexone and Naltrexol In Vitro Pharm. Res. 2008, 25, 1964-1964
12. Gupta, J.; Felner, E. I.; Prausnitz, M. R. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles Diabetes Technol. Ther. 2009, 11 (6) 329-337
13. Gill, H. S.; Prausnitz, M. R. Coated microneedles for transdermal delivery J. Controlled Release 2007, 117, 227-237
14. Milewski, M.; Stinchcomb, A. Vehicle Composition Influence on the Microneedle-Enhanced Transdermal Flux of Naltrexone Hydrochloride Pharm. Res. 2011, 28, 124-134
15. Li, G.; Badkar, A.; Nema, S.; Kolli, C. S.; Banga, A. K. In vitro transdermal delivery of therapeutic antibodies using maltose microneedles Int. J. Pharm. 2009, 368, 109-115
16. Milewski, M.; Pinninti, R. R.; Stinchcomb, A. L. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin J. Pharm. Sci. 2012, 101, 2777-2786
17. Banks, S. L.; Pinninti, R. R.; Gill, H. S.; Paudel, K. S.; Crooks, P. A.; Brogden, N. K.; Prausnitz, M. R.; Stinchcomb, A. L. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs J. Pharm. Sci. 2010, 99, 3072-3080
18. Kalluri, H.; Banga, A. Formation and Closure of Microchannels in Skin Following Microporation Pharm. Res. 2011, 28, 82-94
19. Gupta, J.; Gill, H. S.; Andrews, S. N.; Prausnitz, M. R. Kinetics of skin resealing after insertion of microneedles in human subjects J. Controlled Release 2011, 154 (2) 148-155
20. Brogden, N. K.; Milewski, M.; Ghosh, P.; Hardi, L.; Crofford, L. J.; Stinchcomb, A. L. Diclofenac Delays Micropore Closure Following Microneedle Treatment in Healthy Human Subjects J. Controlled Release 2012, 163 (2) 220-229
21. Feingold, K. R. The outer frontier: the importance of lipid metabolism in the skin J. Lipid Res. 2009, 50 (Suppl.) S417-S422
22. Broughton, G., II; Janis, J. E.; Attinger, C. E. The Basic Science of Wound Healing Plast. Reconstr. Surg. 2006, 117 (7 Suppl.) 12S-34S
23. Mauro, T.; Holleran, W. M.; Grayson, S.; Gao, W. N.; Man, M. Q.; Kriehuber, E.; Behne, M.; Feingold, K. R.; Elias, P. M. Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing Arch. Dermatol. Res. 1998, 290, 215-222
24. Holleran, W. M.; Takagi, Y.; Imokawa, G.; Jackson, S.; Lee, J. M.; Elias, P. M. beta-Glucocerebrosidase activity in murine epidermis: characterization and localization in relation to differentiation J. Lipid Res. 1992, 33, 1201-1209
25. Takagi, Y.; Kriehuber, E.; Imokawa, G.; Elias, P. M.; Holleran, W. M. β-Glucocerebrosidase activity in mammalian stratum corneum J. Lipid Res. 1999, 40, 861-869
26. Grubauer, G.; Feingold, K. R.; Harris, R. M.; Elias, P. M. Lipid content and lipid type as determinants of the epidermal permeability barrier J. Lipid Res. 1989, 30, 89-96
27. Elias, P. M.; Tsai, J.; Menon, G. K.; Holleran, W. M.; Feingold, K. R. The Potential of Metabolic Interventions to Enhance Transdermal Drug Delivery J. Invest. Dermatol. Symp. Proc. 2002, 7, 79-85
28. Schneider, L. A.; Korber, A.; Grabbe, S.; Dissemond, J. Influence of pH on wound-healing: a new perspective for wound-therapy? Arch. Dermatol. Res. 2007, 298, 413-420
29. Gethin, G. The significance of surface pH in chronic wounds Wounds UK 2007, 3, 52
30. scifinder.cas.org: American Chemical Society.
31. National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih. gov.
32. Physicians' Desk Reference, 67 th ed.; PDR Network: Montvale, NJ, 2013.
33. Alkermes Vivitrol (naltrexone for extended release injectable suspension): http://www.vivitrol.com/.
34. Wermeling, D. P.; Banks, S. L.; Hudson, D. A.; Gill, H. S.; Gupta, J.; Prausnitz, M. R.; Stinchcomb, A. L. Microneedles permit transdermal delivery of a skin-impermeant medication to humans Proc. Natl. Acad. Sci. 2008, 105, 2058-2063
35. Milewski, M.; Yerramreddy, T. R.; Ghosh, P.; Crooks, P. A.; Stinchcomb, A. L. In Vitro Permeation of a Pegylated Naltrexone Prodrug Across Microneedle-Treated Skin J. Controlled Release 2010, 146, 37-44
36. Milewski, M. Microneedle-assisted transdermal delivery of naltrexone species. In vitro permeation and in vivo pharmacokinetic studies. University of Kentucky Doctoral Dissertations. 2011; paper 160; http://uknowledge.uky.edu/ gradschool-diss/160.
37. Banks, S.; Paudel, K.; Brogden, N.; Loftin, C.; Stinchcomb, A. Diclofenac Enables Prolonged Delivery of Naltrexone Through Microneedle-Treated Skin Pharm. Res. 2011, 1-9
38. Brogden, N. K. Clinical evalution of novel methods for extending microneedle pore lifetime. Theses and Dissertations-Pharmacy. 2012; paper 8; http://uknowledge.uky.edu/pharmacy-etds/8.
39. Ghosh, P.; Pinninti, R. R.; Hammell, D. C.; Paudel, K. S.; Stinchcomb, A. L. Development of a codrug approach for sustained delivery across microneedle treated skin J. Pharm. Sci. 2013, 102 (5) 1458-1467
40. Brogden, N. K.; Ghosh, P.; Hardi, L.; Crofford, L. J.; Stinchcomb, A. L. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion J. Pharm. Sci. 2013, 10.1002/jps.23544
41. Paudel, K. S.; Nalluri, B. N.; Hammell, D. C.; Valiveti, S.; Kiptoo, P.; Hamad, M. O.; Crooks, P. A.; Stinchcomb, A. L. Transdermal delivery of naltrexone and its active metabolite 6-β-naltrexol in human skin in vitro and guinea pigs in vivo J. Pharm. Sci. 2005, 94, 1965-1975
42. Hadgraft, J.; Valenta, C. pH, pKa and dermal delivery Int. J. Pharm. 2000, 200, 243-247
43. Potts, R. O.; Guy, R. H. Predicting skin permeability Pharm. Res. 1992, 9, 663-669
44. Milewski, M.; Stinchcomb, A. L. Estimation of Maximum Transdermal Flux of Nonionized Xenobiotics from Basic Physicochemical Determinants Mol. Pharmaceutics 2012, 9 (7) 2111-2120
45. Mao-Qiang, M.; Mauro, T.; Bench, G.; Warren, R.; Elias, P. M.; Feingold, K. R. Calcium and potassium inhibit barrier recovery after disruption, independent of the type of insult in hairless mice Exp. Dermatol. 1997, 6, 36-40
46. Curdy, C.; Kalia, Y. N.; Falson-Rieg, F.; Guy, R. H. Recovery of human skin impedance in vivo after iontophoresis: effect of metal ions AAPS PharmSci 2000, 2, E23